
Bioengineered Chewing Gum Targets HPV and Harmful Oral Bacteria Linked to Head and Neck Cancer
Researchers from the University of Pennsylvania developed a lablab-bean–based bioengineered chewing gum that releases FRIL antiviral protein and Protegrin antimicrobial peptide to reduce HPV levels (up to 93% in saliva) and two cancer-linked bacteria (Porphyromonas gingivalis and Fusobacterium nucleatum) in lab tests, while largely sparing beneficial oral bacteria. The gum is not yet publicly available and is not a substitute for HPV vaccination, regular screenings, or medical treatment; more clinical trials are needed to determine whether regular use could lower cancer risk or improve outcomes.













